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Abstract
Background/Objectives: Protein tyrosine phosphatase non-
receptor type 23 (PTPN23) has recently been associated with 
several human epithelial cancers via regulation of growth 
factor signaling. Colorectal carcinoma (CRC) is a leading 
cause for cancer-related death worldwide and is associated 
with aberrant epidermal (EGF) and vascular endothelial 
growth factor signaling. Here, we investigated whether 
PTPN23 might play a role in CRC. Methods: Expression of 
PTPN23 was analyzed in CRC tissue by immunohistochemis-
try. PTPN23 was silenced in HT-29 cells to address the role of 
PTPN23 in EGF signaling, gene expression, and cell migra-
tion. Results: PTPN23 silencing in HT-29 and Caco-2 intesti-
nal epithelial cancer cells significantly enhanced activation 
of pro-oncogenic signaling molecules and genes promoting 
epithelial-to-mesenchymal transition (EMT) upon EGF treat-
ment, while genes encoding tight junction proteins were 
significantly reduced. Conclusions: Our data clearly indicate 
that loss of PTPN23 is associated with increased activation of 
pro-oncogenic signaling pathways and an enhanced ability 
of human intestinal cancer cells to undergo EMT. Taken to-
gether, these findings show that PTPN23 acts as a tumor sup-
pressor gene in CRC. © 2019 S. Karger AG, Basel
Introduction
Colorectal carcinoma (CRC) is the third most com-
mon cancer worldwide in both men and women. Up to 
70–80% of CRC develop sporadically, whereby somatic 
mutations mediate progression through the adenoma-
carcinoma sequence [1]. These mutations, such as genet-
ic mutations in the oncogene KRAS, which is found in 
40% of CRC patients, result in altered response to growth 
factor receptors, indicating that deregulated growth re-
ceptor signaling is crucially involved in CRC pathogene-
sis. Beside this, genetic syndromes such as the hereditary 
nonpolyposis colorectal cancer syndrome, familial ade-
nomatous polyposis, and the Peutz-Jeghers syndrome 
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make in total up to 5.1% of CRC cases [2]. Further, life-
style factors, including a diet low in fibers and high in red 
meat, a high body weight, alcohol consumption, low 
physical activity, and advanced age are well-known risk 
factors for the development of CRC [1]. Most CRC cases 
are diagnosed in Western countries with an annual in-
crease in incidence [3]. Whether the tumor has metasta-
sized to lymph nodes or distant organs is a key factor in 
determining patient survival [4]. More than 50% are di-
agnosed with metastasis at or beyond stage III of the 
American Joint Committee on Cancer (AJCC) tumor/
node/metastasis (TNM) staging system. In case of CRC 
metastases, 5-year survival rate drops from 60 to 10% [5]. 
CRC is the fourth most common cause of cancer-related 
death worldwide [3], and investigation of the risk factors 
and molecular mechanisms involved in CRC pathophys-
iology is an important task to identify novel therapeutic 
targets.
Cells that acquire invasive and metastatic characteris-
tics by sporadic epigenetic modifications are typical for 
the malignant progression of CRC. One such process, 
which allows cells to obtain invasive and metastatic po-
tential, is the so-called epithelial-to-mesenchymal transi-
tion (EMT). During EMT, polarized epithelial cells lose 
their characteristics and undergo tight junction detach-
ment, impairment in apical-basal polarity, and reorgani-
zation of cytoskeletal architecture, and thereby gain mes-
enchymal properties such as increased motility. Growth 
factors, inflammatory cytokines, and hypoxia regulate 
EMT in cancer cells, allowing the malignant cells to adapt 
to the tumor microenvironment and to develop an inva-
sive and metastatic phenotype [6]. Of note, targeting epi-
dermal growth factor (EGF) and vascular endothelial 
growth factor (VEGF) signaling is a well-established ther-
apeutic approach in CRC treatment.
Protein tyrosine phosphatase (PTP) nonreceptor type 
23 (PTPN23, also known as His domain-containing PTP 
[HD-PTP]), has recently been associated with mammary 
epithelial cancer development via regulation of EMT and 
subsequent disruption of the E-cadherin/β-catenin asso-
ciation [7]. PTPN23 is a member of the PTP family, which 
removes phosphate groups from phosphorylated tyrosine 
residues on target proteins, including surface receptors 
and downstream signaling molecules. In that way, PTPs 
regulate signal transduction events involved in cell dif-
ferentiation, proliferation, apoptosis, adhesion, motility, 
invasion, and migration [7, 8]. Further, PTPN23 regu-
lates EGF receptor (EGFR) cell surface expression in 
many cell types [9]. Of note, EGF and EGFR play an im-
portant role in wound repair and cell growth [10]. PTPN23 
forms part of the endosomal sorting complexes required 
for transport (ESCRT) pathway, which mediates EGFR 
internalization and endosomal degradation. PTPN23 de-
letion in epithelial cervix carcinoma cells leads to a stabi-
lization of EGFR on the cell surface likely resulting in in-
creased downstream signaling pathway activation [9].
The gene locus encoding PTPN23 is located on the 
vulnerable chromosomal region 3p21.3, a hot spot for de-
letion in human epithelial cancers [11], including breast 
cancer and epithelial cervix carcinoma, but also testicular 
germ cell tumors, lung, skin, prostate, and esophagus 
cancers [12]. Although, the role of PTPN23 in the patho-
physiology of some epithelial tumors has been described, 
its role in colon cancer cells has not yet been identified. 
Therefore, the aim of this study was to investigate the role 




The following TaqMan genotyping assays were obtained from 
Thermo Fisher (Waltham, MA, USA): PTPN23 (Hs00394144_m1), 
CDH1 (Hs01023894_m1), ETS1 (Hs00428293_m1), ITGB6 
(Hs00168458_m1), EGFR (Hs01076078_m1), occludin 
(Hs00170162_m1), vimentin (Hs00185584_m1), zonulin-1 
(Hs01551861_m1), DKK1 (Hs00183740_m1), and SNAIL 
(Hs00195591_m1). Antibodies against human phosphorylated 
(Tyr416)/total Src, EGFR, phosphorylated (Tyr397)/total FAK; phos-
phorylated (Ser473)/total Akt; phosphorylated (Tyr202/204) extracel-
lular signal-regulated kinase (ERK); phosphorylated (Tyr705)/total 
STAT3; E-cadherin, and phosphorylated (Ser552)/total β-catenin 
were obtained from Cell Signaling Technologies (Danvers, MA, 
USA). Anti-human PTPN23 and anti-β-actin antibodies were ob-
tained from Sigma Aldrich (St. Louis, MO, USA), and anti-human 
total ERK antibody from Millipore (Burlington, MA, USA).
Cell Culture
Human colonic HT-29 and Caco-2 epithelial cancer cells were 
obtained from DMSZ and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Life Technologies, Paisley, UK) supplemented 
with 0.1% nonessential amino acids (NEAA; Life Technologies) 
and 10% fetal calf serum (FCS; PAN Biotech, Brunschwig, Switzer-
land). Cells were grown in a 10% CO2 atmosphere and detached 
using trypsin before seeding 1 × 106 cells/well on 12-well tissue 
culture plates.
siRNA Transfection
Directly before siRNA transfection, the cell culture medium 
was changed to culture medium without FCS (SF-DMEM). Knock-
down of PTPN23 was then achieved using 3 human PTPN23 si-
lencer predesigned siRNA constructs from Life Technologies at a 
concentration of 5 nmol/mL. For transfection, all 2 PTPN23-spe-
cific siRNA constructs were mixed with Lipofectamine RNAiMax 
(Life Technologies, Carlsbad, CA, USA) and incubated at room 
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temperature for 20 min before adding to the cell culture media (SF-
DMEM). After 8 h, medium was changed to DMEM supplement-
ed with 0.1% MEM NEAA and 10% FCS, and cells were cultured 
for another 24 h before further treatment. 
Cell Activation
For EGF (R&D) treatment, cell culture medium was supplant-
ed by SF-DMEM in order to minimize interference of growth fac-
tors present in the FCS with the experiments. After 8 h, cells were 
stimulated with EGF (100 ng/mL) for 30 min for protein isolation 
or for 24 h for RNA isolation unless specified otherwise. 
Cell Lysates
After stimulation, the cells were washed twice in ice-cold Dul-
becco’s phosphate-buffered saline (PBS, without calcium chloride 
and magnesium chloride; Sigma Aldrich) and lysed in the assay-
specific buffer.
RNA Isolation and RT-PCR
Isolation of total RNA was performed using the RNeasy mini 
kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. RNA concentration was measured using a NanoDrop 
spectrophotometer (ND-1000; Witec AG, Littau, Switzerland). 
Complementary DNA (cDNA) synthesis was performed using the 
HighScribe reverse transcriptase kit (Applied Biosystems, Thermo 
Fisher). Real-time PCR was performed using FAST qPCR master 
mix (Thermo Fisher Scientific) on an RT-PCR QuantStudio 6 Flex 
system. All measurements were performed in triplicate, human 
GAPD (endogenous control [VIC, MGB probe], Applied Biosys-
tems, Thermo Fisher) was used as endogenous control, and results 
were analyzed using the ΔΔCT method. The real-time PCR con-
tained an initial enzyme activation step (5 min, 95  ° C) followed by 
45 cycles consisting of a denaturing (95  ° C, 15 s) and an annealing/
extending (60  ° C, 1 min) step.
Protein Isolation and Western Blots
Proteins were isolated using mammalian protein extraction re-
agent (M-Per; Fisher Scientific) according to the manufacturer’s 
instructions. Equal amounts of proteins from each lysate were load-
ed on polyacrylamide gels and blotted onto nitrocellulose mem-
branes after separation by gel electrophoresis. Membranes were 
blocked in a 1% BSA and 3% milk containing blocking solution and 
incubated overnight in blocking solution with an appropriate con-
centration of primary antibody. Membranes were washed 3 times 
with washing buffer (Tris-buffered saline containing 1% Tween 20) 
before incubation with HRP-coupled anti-rabbit secondary anti-
body (Lab Force, Santa Cruz, CA, USA) for 2 h. Immunoreactive 
proteins were detected with a Fusion Solo S imager (Vilber Lour-
mat; Witec AG) using a Western blotting detection kit (Western 
Bright Sirius or ECL; Advansta, Menlo Park, CA, USA).
Immunoprecipitation and Detection of Phosphorylated EGFR
To detect EGFR phosphorylation, 150 μg of protein was pre-
cleared on a shaker with Sepharose G beads (GE Healthcare, Little 
Chalfont, UK) for 30 min prior to incubation at 4   ° C with 5 μg 
anti-EGFR antibody overnight. Antibody-bound protein was then 
precipitated using Sepharose G beads according to the manufac-
turer’s instructions and washed 3 times in ice-cold PBS; precipi-
tates were heated in 20 μL 1× loading buffer (Invitrogen, Carlsbad, 
CA, USA) for 10 min, and supernatants were used for Western 
blots as described above. To detect phosphorylated tyrosine resi-
dues, an HRP-labeled, mouse anti-phosphotyrosine antibody 
(PY20; Cell Signaling Technologies) was used. 
Electric Cell Substrate Impedance Sensing
Electric cell substrate impedance sensing (Applied BioPhysics, 
Trogy, NY, USA) is a real-time, impedance-based method used to 
quantify cell behavior considering cell-cell contacts; 100,000 HT-
29 cells/well were seeded on two 1E/8W plates (IBIDI, Planegg, 
Germany) and grown until confluency for 5 days. siRNA transfec-
tion was performed as described above. Two days later, medium 
was changed to SF-DMEM 8 h before cells were wounded by ap-
plying a current of 2,000 mA for 20 s at a frequency of 60,000 Hz. 
Cells were washed with PBS prior to treatment with EGF (100 ng/
mL). Resistance and capacitance measurements were collected in 
real time at 64,000 Hz (capacitance) and 4,000 Hz (resistance). Ob-
tained values were normalized to the offset point at the time of 
wounding.
Flow Cytometry
For flow cytometry, HT-29 cells were seeded in 24-well plates 
at a density of 0.5 × 106 cells/well and transfected with siRNA pri-
or to EGF treatment as described above. At indicated time points, 
cells were washed in ice-cold PBS, detached from the culture plate 
using 1% trypsin/EDTA for 5 min, and washed once in FCS con-
taining culture medium to stop surface protein degradation. Cells 
were then washed again with PBS and incubated on ice with rabbit 
anti-human EGFR (Cell Signaling) and the Zombie NIR live-death 
discriminator for 15 min. Cells were again washed and incubated 
for 10 min with AlexaFluor647-labeled anti-rabbit antibody (Cell 
Signaling) prior to fixation with the FoxP3 fixation/permeabiliza-
tion kit from eBioscience. Cells were then incubated for another 
15 min with PE-Texas Red-coupled anti Ki67 antibody (BioLeg-
end, San Diego, CA, USA). After washing, cells were analyzed on 
an LSRFortessa from BD. For annexin V/propidium iodide (PI) 
staining to discriminate apoptotic cells, cells were detached from 
the culture plate as described above prior to incubation in annexin 
binding buffer (10 mM HEPES, 150 mM NaCl, 2.5 mM CaCl2 in 
PBS, pH 7.4) for 10 min. Cells were then stained with annexin V 
and PI (both from Thermo Fisher Scientific) for 10 min at room 
temperature prior to washing in annexin binding buffer and anal-
ysis on an BD LSRFortessa.
Statistical Analysis
Data are normalized to the respective control and presented as 
mean ± SD. Statistical analyses were conducted by ANOVA fol-
lowed by the Student-Newman-Keuls test or Man-Whitney U test 
where appropriate. p values < 0.05 were considered significant. 
Results
EGF Treatment Induces PTPN23 Expression in HT-29 
and Caco-2 Cells
In a first step to investigate a possible role for PTPN23 
in the pathogenesis of CRC, we investigated whether EGF 
stimulation affects PTPN23 expression in human colonic 
cancer cell lines. Therefore, we treated the human colon 




































































































































































































Fig. 1. Epidermal growth factor (EGF) stimulation induces 
PTPN23 expression. HT-29 cells were treated with 100 ng/mL EGF 
for the indicated times (a, b). Real-time PCR analysis shows 
PTPN23 mRNA expression normalized to GAPDH and untreated 
control (Ctr) cells (a). Representative pictures from Western blot 
analysis of PTPN23 protein and respective densitometric analysis 
(b). c, d HT-29 cells were treated with 100 ng/mL EGF, 100 ng/mL 
VEGF, 100 ng/mL TNF, or a combination of EGF + VEGF or EGF 
+ TNF for 24 h. c Real-time PCR analysis shows PTPN23 mRNA 
expression normalized to GAPDH and untreated control cells. 
d Representative pictures from Western blot analysis of PTPN23 
protein and respective densitometric analysis. e, f Caco-2 cells 
were treated with 100 ng/mL EGF for the indicated times. e Real-
time PCR analysis shows PTPN23 mRNA expression normalized 
to GAPDH and untreated control cells. f Representative pictures 
from Western blot analysis of PTPN23 protein and respective den-
sitometric analysis. Data are normalized to the average of the un-
treated control group and β-actin. n = 5; mean ± SD; * p < 0.05, vs. 
untreated control cells (one-way ANOVA). 
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cancer cell line HT-29 with 100 ng/mL EGF for up to 
48 h and analyzed PTPN23 mRNA and protein expres-
sion by real-time PCR and Western blotting, respectively. 
As shown in Figure 1a, we found an increase in the 
PTPN23 mRNA level with significant differences after 8 
and 24 h of EGF stimulation (p < 0.05) in HT-29 cells. 
Figure 1b confirms a significant increase in protein ex-
pression (p < 0.05). These data show that EGF induces 
PTPN23 expression, which indicates that PTPN23 might 
be involved in regulating EGF-mediated signaling cas-
cades in HT-29 cells. Of note, other factors involved in 
tumor growth and progression, such as tumor necrosis 
factor (TNF) and VEGF, did also induce PTPN23 mRNA 
and protein expression (Fig.  1c, d). However, co-treat-
ment of EGF with TNF or EGF with VEGF did not further 
enhance PTPN23 levels (Fig. 1c, d). Of note, PTPN23 also 
promoted PTPN23 expression in a second colon cancer 
cell line, namely Caco-2 cells (Fig. 1e, f).
Loss of PTPN23 Results in Decreased EGFR 
Degradation upon EGF Treatment
In a next step, we investigated whether EGF treatment 
affects cell surface EGFR localization in HT-29 and Caco-
2 cells and whether PTPN23 is involved in EGFR degra-
dation. Therefore, we transfected HT-29 and Caco-2 cells 
with PTPN23-specific or with control siRNA; 24 h after 
siRNA transfection, cells were stimulated with 100 ng/mL 
EGF for the indicated times (Fig. 2a, b), and EGFR ex-
pression was analyzed by Western blotting. Figure 2a and 
2b shows a clear reduction in EGFR expression in HT-29 
and Caco-2 cells after EGF stimulation at all time points. 
Interestingly, PTPN23 knockdown led to a significant in-
crease in EGFR protein expression compared to control 
cells independent of EGF stimulation (p < 0.01). It has 
been demonstrated that loss of PTPN23 results in re-
duced internalization of EGFR in cervix carcinoma cells 
[9]. Therefore, we next analyzed surface expression of 
EGFR in HT-29 cells upon silencing of PTPN23 and 
treatment with EGF for 30 min, and 1, 2, and 4 h. As ex-
pected, EGF treatment resulted in a clear reduction in 
EGFR surface expression already after 30 min (Fig. 2c). 
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Fig. 2. PTPN23 promotes EGFR degradation. HT-29 (a, c) and 
Caco-2 (b) cells were transfected with either PTPN23-specific 
 siRNA or nontargeting control siRNA (Ctr) followed by EGF stim-
ulation with 100 ng/mL for the indicated times. a, b Representative 
pictures from Western blot analysis and densitometric analysis 
show EGFR protein expression after 1, 2, and 4 h of EGF stimula-
tion compared to untreated control cells. c EGFR surface expres-
sion on HT-29 cells after 30 min, and 1 and 2 h of EGF stimulation 
compared to unstimulated control cells was analyzed by flow cy-
tometry. Data are representative for 3 independent experiments. 


























































































































































































































































































Fig. 3. PTPN23 regulates phosphorylation and thereby activation 
of Src, focal adhesion kinase (FAK), β-catenin, and ERK in HT-29 
cells. PTPN23-specific siRNA and nontargeting control siRNA-
transfected HT-29 cells were treated with EGF (100 ng/mL) for 30 
min. Shown are representative pictures from Western blot analysis 
and the respective densitometric analysis of PTPN23 (a); phos-
phorylated and total EGFR from EGFR immunoprecipitates (b); 
phospho- and total Src (c); phospho- and total FAK (d); phospho- 
and total β-catenin (e); E-cadherin (f); phospho- and total ERK 
protein (g); and phospho- and total Akt (h). Data are normalized 
to β-actin and the untreated, control (Ctr) siRNA-transfected cells. 
n = 5; mean ± SD; * p < 0.05, ** p < 0.01, vs. the relative control 
(one-way ANOVA).
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Further, silencing of PTPN23 affected degradation of 
EGFR from the cell surface and led to an increase in EGFR 
surface stabilization after a 30-min EGF stimulation in 
PTPN23-knockdown cells compared to control cells. 
These data demonstrate that in HT-29 cells, EGFR sur-
face expression is regulated by PTPN23. Nevertheless, we 
still noticed a reduction in EGFR surface expression in 
PTPN23-knockdown cells upon EGF presence. 
PTPN23 Regulates Src, FAK, β-Catenin, and ERK 
Activation
Having shown that PTPN23 regulates EGFR degrada-
tion in HT-29 cells, we investigated its effect on the phos-
phorylation status of EGFR. For this aim, we transfected 
HT-29 cells again with PTPN23-specific siRNA, or non-
targeting control siRNA. As demonstrated in Figure 3a, 
treatment with PTPN23-specific siRNA resulted in a 
clear reduction in PTPN23 protein expression. Immuno-
precipitation of EGFR and subsequent analysis of tyro-
sine phosphorylation revealed that tyrosine phosphoryla-
tion and thereby activation of EGFR was significantly in-
creased in PTPN23-deficient cells compared to control 
cells (p < 0.01; Fig. 3b).
We further investigated whether EGFR downstream 
signaling pathways were differentially activated upon 
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Fig. 4. PTPN23 regulates phosphorylation and thereby activation 
of Src, FAK, β-catenin, and ERK in Caco-2 cells. PTPN23-specific 
siRNA and nontargeting control (Ctr) siRNA-transfected Caco-2 
cells were treated with EGF (100 ng/mL) for 30 min. Shown are 
representative pictures from Western blot analysis and the respec-
tive densitometric analysis of PTPN23 (a); phosphorylated and to-
tal EGFR from EGFR immunoprecipitates (b); phospho- and total 
Src (c); phospho- and total FAK (d); β-catenin (e); and representa-
tive phospho- and total ERK protein expression (f). Data are nor-
malized to β-actin and the untreated, control siRNA-transfected 
cells. n = 3; mean ± SD; * p < 0.05, vs. the relative control (one-way 
ANOVA). 
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EGF treatment Src and focal adhesion kinase (FAK) 
phosphorylation are significantly higher in PTPN23-de-
ficient cells than control cells (100 ng/mL for 30 min, p < 
0.05 and p < 0.01, respectively). FAK is a cytoplasmic ty-
rosine kinase involved in cell migration. Further, we 
found significantly increased β-catenin phosphorylation 
in EGF-treated PTPN23-deficient cells compared to con-
trol cells (p < 0.05; Fig. 3e), while E-cadherin protein lev-
els were not affected in PTPN23-deficient cells (Fig. 3f). 
ERK phosphorylation was significantly increased in 
PTPN23-deficient cells compared to control cells after 
EGF stimulation (p < 0.05; Fig. 3g). On the other hand, 
surprisingly, silencing of PTPN23 did not affect EGF-in-
duced Akt phosphorylation upon deletion of PTPN23 
(Fig. 3h).
Similar results were obtained with EGF-treated Caco-
2 cells upon PTPN23 silencing: in these cells, we also ob-
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Fig. 5. PTPN23 knockdown leads to loss of tight junctions and gain 
of epidermal-to-mesenchymal transition (EMT) at mRNA level in 
HT-29 cells. HT-29 cells were transfected with either PTPN23-
specific siRNA or nontargeting control siRNA before treatment 
with EGF (100 ng/mL) for 24 h. The graphs show mRNA levels of 
PTPN23 and EGFR (a); mRNA levels of SNAIL and DKK1 (b); 
mRNA expression of CDH1, OCLN, and ZO1 (c), and mRNA ex-
pression of VIM, ETS1, and ITGB6 (d), and TP53 (e). All data are 
normalized to the untreated control group and GAPDH. n = 5; 
mean ± SD; * p < 0.05, ** p < 0.01, vs. the relative control (one-way 
ANOVA).
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as downstream Src, FAK, β-catenin, and ERK phosphor-
ylation (Fig. 4). These data indicate that PTPN23 plays a 
role in pro-oncogenic signaling pathways induced upon 
EGFR activation. 
PTPN23-Knockdown Leads to Loss of Tight Junctions 
and Gain of EMT at mRNA Level
In a next step, we addressed how silencing of PTPN23 
affects mRNA expression of EGF-induced genes in HT-
29 cells. As expected, treatment with PTPN23 siRNA re-
sulted in an efficient reduction in PTPN23 mRNA levels 
(p < 0.01; Fig. 5a). Of note, mRNA levels of EGFR did not 
show a significant difference when HT-29 cells were 
transfected with PTPN23-specific siRNA.
Having demonstrated an increase in Src, FAK, 
β-catenin, and ERK activation (phosphorylation) at pro-
tein level in PTPN23-deficient cells, we now investigated 
the mRNA levels of their target genes. We found a sig-
nificant increase in mRNA levels of the transcription fac-
tor SNAIL in nonstimulated PTPN23-deficient cells 
compared to control cells (p < 0.01; Fig. 5b). On the other 
hand, the β-catenin antagonist DKK1 [6] was significant-
ly reduced in EGF-stimulated PTPN23-competent cells 
and even further reduced upon loss of PTPN23 compared 
to cells expressing normal levels of PTPN23 (p < 0.05; 
Fig. 5b). We further investigated genes encoding for tight 
junction proteins such as CDH1 (encoding E-cadherin), 
OCLN (occludin), and ZO1 (zonulin-1) [6]. Figure 5c 
shows a significant reduction in CDH1 and ZO1 levels in 
PTPN23-knockdown cells, which was further pro-
nounced through EGF stimulation (p < 0.05). On the oth-
er hand, PTPN23 deletion had no significant impact on 
OCLN mRNA levels. At the same time, we found signifi-






































































































































































































































Fig. 6. PTPN23 knockdown leads to loss of tight junctions and gain 
of epidermal-mesenchymal transition (EMT) at mRNA level in 
Caco-2 cells. Caco-2 cells were transfected with either PTPN23-
specific siRNA or nontargeting control (Ctr) siRNA before treat-
ment with EGF (100 ng/ml) for 24 h. The graphs show mRNA 
levels of PTPN23 (a); CDH1 (b); ZO1 (c); DKK1 (d); VIM (e), and 
ETS1 (f). All data are normalized to the untreated control group 
and GAPDH. n = 3; mean ± SD; * p < 0.05, vs. the relative control 
(one-way ANOVA).
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Fig. 7. Loss of PTPN23 leads to an increase in migration and pro-
liferation and to a decrease in apoptosis. Transfection with either 
PTPN23-specific siRNA or nontargeting control (Ctr) siRNA was 
performed as described above. a Wounding with electric cell sub-
strate impedance sensing (ECIS) was conducted prior to treatment 
with EGF (100 ng/mL). ECIS measured capacitance over time. 
Data are shown in comparison to the untreated relative control 
group and capacitance at the time of wounding. The lines show 
averages from 4 independent measurements for each condition. 
HT-29 (b) and Caco-2 cells (c) were stimulated with EGF (100 ng/
mL) for either 1, 2, or 4 h. The percentage of Ki67+ (proliferating) 
cells was analyzed by flow cytometry. Data are presented as per-
centage of the untreated relative control group in densitometric 
analysis. d–f The rate of early and late apoptosis and necroptosis 
was analyzed by flow cytometry using the markers annexin V and 
propidium iodide (PI). The graph shows representative FACS dot 
plots (d) and statistical analysis of HT-29 (e) and Caco-2 cells (f). 
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cules characteristic for a mesenchymal cell phenotype, 
such as VIM and ETS1 (p < 0.05; Fig.  5d). Integrin β6 
(ITGB6) and tumor suppressor gene TP53 mRNA levels 
were not significantly altered (Fig. 5d, e). These data dem-
onstrate a clear correlation between PTPN23 loss of func-
tion and an increase in EMT-enhancing factors at mRNA 
level. 
Again, similar results were obtained with Caco-2 cells, 
where we found reduced levels of epithelial phenotype 
markers, including CDH1, ZO1, and DKK1, while factors 
associated with EMT, such as VIM and ETS1, were in-
creased in EGF-treated Caco-2 cells (Fig. 6).
Loss of PTPN23 Results in Increased Proliferation and 
Migration and Decreased Apoptosis
Having demonstrated that PTPN23 deficiency im-
pacts pro-oncogenic signaling pathways and EMT-asso-
ciated gene transcription events in human HT-29 colon 
cancer cells, we next investigated migration and prolif-
eration of HT-29 cells upon loss of PTPN23. To investi-
gate how loss of PTPN23 affects cell migration and 
wound closure, we seeded HT-29 cells in electric cell 
substrate impedance sensing plates where wound clo-
sure can be assessed via capacitance measurements. Five 
days after seeding, when cells were 80% confluent, 
PTPN23 was silenced using siRNA. Two days later, a 
wound was induced in the epithelial layer prior to treat-
ment with EGF (100 ng/mL), and capacitance was mea-
sured for several hours. As shown in Figure 7a, cells 
treated with PTPN23-specific siRNA grew much faster 
back to confluency than control cells, leading to a faster 
reduction in capacitance. Of note, EGF treatment fur-
ther enhanced this effect. To confirm this finding, we 
next analyzed the percentage of proliferating cells by 
flow cytometry using the proliferation marker Ki67. 
Compared to control cells, loss of PTPN23 led to sig-
nificantly more Ki67+ (proliferating) cells after 2 and 
4 h of EGF stimulation (p < 0.05; Fig. 7b, c). To further 
address whether deletion of PTPN23 affects apoptosis, 
we used annexin V and PI in flow cytometry. The rate of 
late apoptosis and necroptosis was significantly de-
creased in PTPN23-deficient cells compared to control 
cells, but this was not affected by EGF stimulation (p < 
0.05; Fig. 7d–f). These data indicate that PTPN23 defi-
ciency leads to significant changes in human colonic ep-
ithelial cancer cell behavior including proliferation, mi-
gration, late apoptosis, and necroptosis. 
Discussion
In the present study, we demonstrate that EGF stimu-
lation results in increased PTPN23 expression in human 
colonic HT-29 and Caco-2 epithelial cancer cells and that 
PTPN23 in turn regulates EGF-induced signaling cas-
cades, EMT, cell migration, and proliferation. These ob-
servations suggest for the first time that PTPN23 might 
be involved in the pathogenesis of colorectal carcinoma.
Besides inflammatory cytokines and hypoxia, growth 
factors such as EGF have been demonstrated to be elevat-
ed in the tumor microenvironment [6]. Our results indi-
cate that increased levels of PTPN23 upon EGF treatment 
might protect cells from abnormally regulated EMT 
through dephosphorylation and thereby inactivation of 
EGF-induced signaling pathways. EGF treatment results 
in internalization and degradation of EGFR. A recent 
study showed a correlation between PTPN23 deficiency 
in epithelial cervix carcinoma cells and stabilization of 
EGFR on the cell surface [9]. There, Ali et al. [9] demon-
strated that PTPN23 is part of the ESCRT pathway that 
mediates EGFR internalization and endosomal degrada-
tion. In their experiments, PTPN23 deletion resulted in 
diminished EGFR release from ESCRT-0 to ESCRT-III, 
likely resulting in increased EGFR downstream signaling 
pathway activation. Interestingly, we also found a corre-
lation between PTPN23 deficiency and EGFR surface sta-
bilization in human HT-29 cells, indicating that the role 
of PTPN23 as part of the ESCRT pathway is not cell type 
specific but rather a universal mechanism.
We have also demonstrated that PTPN23 regulates 
several signaling molecules downstream of EGFR. A re-
cent publication showed that knockout of PTPN23 in 
mammary epithelial cells was associated with enhanced 
activation and autophosphorylation of FYN, a member of 
the Src kinase family [11]. Enhanced FYN phosphoryla-
tion upon loss of PTPN23 leads to increased phosphory-
lation of the cytoplasmic segment of E-cadherin and 
Tyr142 of β-catenin, finally resulting in the disruption of 
the E-cadherin/β-catenin association [11]. As a conse-
quence, E-cadherin is internalized in early endosomes by 
endocytosis, and thereby elevated FYN activation results 
in impaired integrity of adherens junctions. β-Catenin 
activation in turn increases mesenchymal protein expres-
sion and promotes EMT [7]. In our study, we demon-
strate that knockdown of PTPN23 in HT-29 and Caco-2 
cells leads to similar results, with significantly enhanced 
Src phosphorylation upon PTPN23 deletion. Src is a pro-
tein tyrosine kinase and one of the best-investigated pro-
oncogenic molecules, which regulates major cancer-pro-
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moting cellular mechanisms, including proliferation, dif-
ferentiation, and survival [13]. Apart from increased Src 
phosphorylation, silencing of PTPN23 also promotes 
FAK activation. In its activated state, FAK forms a com-
plex with Src and activates signaling pathways that pro-
mote cell migration and angiogenesis [14]. With ERK be-
ing a member of the mitogen-activated protein kinases, 
another signaling molecule controlling cell growth, mi-
gration and apoptosis is significantly up-regulated in 
PTPN23-deficient HT-29 and Caco-2 cells [15].
A further link to cell migration upon loss of PTPN23 can 
be drawn when considering that mRNA levels of CHD1, 
which encodes E-cadherin, are significantly reduced in 
PTPN23-deficient cells. E-cadherin is a transmembrane 
glycoprotein that links epithelial cells at adherens junctions 
and exerts a tumor-suppressive function through growth 
inhibition, reduction of invasiveness, apoptosis, as well as 
differentiation, and thereby protects from EMT. Reduced 
E-cadherin expression is associated with poor prognosis 
and survival in various human cancers, such as breast can-
cer and liver carcinoma [16]. Beside this, E-cadherin inhib-
its β-catenin and in this way dampens transcription of 
downstream target genes of the proliferative Wnt signaling 
pathway [16]. In line with a tumor suppressive role for 
PTPN23, we detected a significant increase in phosphory-
lated β-catenin protein levels in PTPN23-deficient human 
HT-29 and Caco-2 cells. Due to its function in enhancing 
Wnt signaling, β-catenin can be regarded as a proto-onco-
gene [17], and elevation of β-catenin has been found in 
sporadic CRC [18] and other tumors [17].
EMT is induced through different signaling pathways, 
one of them being the Wnt/β-catenin pathway. Wnt sig-
naling induces translocation of β-catenin to the nucleus, 
increases levels of SNAIL and vimentin, and suppresses 
the expression of E-cadherin. SNAIL is a transcription 
factor, which is early activated in EMT and thereby plays 
an important role in cancer development. Its overexpres-
sion is associated with invasiveness, metastasis, and de-
creased survival of CRC patients [6]. Our findings clearly 
point towards an increased potential for EMT in PTPN23-
deficient CRC cells. Upon PTPN23 knockdown, HT-29 
and Caco-2 cells show a significant induction of SNAIL, 
while the Wnt/β-catenin antagonist DKK1, is significant-
ly reduced. On the other hand, genes encoding tight junc-
tion proteins, namely CDH1 and OCLN, which are both 
regulated by SNAIL [6], and ZO1, which interacts with 
occludin to organize epithelial polarization [19], are sig-
nificantly reduced. Further, genes that promote mesen-
chymal characteristics, such as VIM and ETS1, are signif-
icantly increased upon PTPN23 silencing – possibly indi-
rectly via increased SNAIL expression/activity. Among 
these, increased ETS1 expression is of great interest, since 
its protein product, c-ets-1, contributes to cancer cell in-
vasiveness and neo-angiogenesis, and high c-ets-1 levels 
are associated with poor survival in cancer patients [20].
Our data indicate that loss of PTPN23 is associated 
with increased activation of pro-oncogenic signaling 
pathways and enhanced ability of colonic epithelial cells 
to undergo EMT. EMT is associated with aberrant cell 
proliferation, reduced apoptosis, poor differentiation, in-
creased motility, invasiveness, metastasis, and neo-angio-
genesis [6]. In line with this, PTPN23-deficient HT-29 
cells showed a clear increase in cell migration, a signifi-
cant increase in proliferation, and significant decreases in 
late apoptosis and necroptosis. 
Of interest, PTPN23-deficient cells showed reduced 
levels of apoptosis/necroptosis even without EGF stimu-
lation. Cell preparation for flow cytometry involves me-
chanical dissociation of cell-cell contacts to achieve single 
cell suspensions, resulting in cellular stress and low levels 
of apoptosis since intestinal epithelial cells are sensitive to 
apoptosis once they lose cell-cell and extracellular matrix 
contacts [21], a mechanism called anoikis [22]. Reduced 
sensitivity to anoikis in PTPN23-knockdown cells further 
indicates that loss of PTPN23 promotes survival of trans-
formed intestinal epithelial cells when they undergo EMT 
and dissociate from the epithelium.
Taken together, our data show that PTPN23 acts as a 
tumor suppressor gene in CRC. Presence of EGF results 
in enhanced PTPN23 expression in human colonic HT-
29 and Caco-2 epithelial cancer cells, leading to a signifi-
cant down-regulation of pro-oncogenic downstream sig-
naling pathways, such as Src, FAK, β-catenin, and ERK. 
Upon loss of PTPN23, genes encoding tight junction pro-
teins are significantly reduced, while EMT-enhancing 
genes are significantly up-regulated. Our data confirm 
functional changes in PTPN23-deficient human colonic 
HT-29 epithelial cancer cell behavior, leading to signifi-
cantly increased proliferation, increased migration, and 
significantly decreased late apoptosis and necroptosis. 
This indicates that loss of PTPN23 might be involved in 
the transition from noninvasive tumor cells to cancer 
cells with metastatic potential [23]. Nevertheless, further 
studies are needed to address the in vivo role of PTPN23 
during colon cancer development.
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